Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation
- 5 October 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (103) , 103ra99
Abstract
Modeling survival and death signaling in tumors by combining quantitative imaging and in situ biomarker analysis can be used to predict responses to therapy after oncogene inactivation.Keywords
This publication has 64 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenesCancer Cell, 2006
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Intrinsic tumour suppressionNature, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Overdiagnosis in chest radiographic screening for lung carcinomaCancer, 2003